Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients

Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients

BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2i) are a novel medication for treating type 2 diabetes (T2DM), which have the pleiotropic effect of weight reduction. This study aimed to evaluate clinical and biochemical predictors of effective weight reduction in T2DM patients who use vari...

Full description

Bibliographic Details
Main Authors:	Pojsakorn Danpanichkul, Worapaka Manosroi, Tharadon Nilsirisuk, Theetouch Tosukhowong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Endocrinology
Subjects:	SGLT2 inhibitors weight reduction diabetes mellitus type 2 weight loss diabetes
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1251798/full

Similar Items

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
by: Hyun A Cho, et al.
Published: (2017-06-01)

Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis
by: Worapaka Manosroi, et al.
Published: (2022-11-01)

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study
by: Chang-Yuan Hsu, et al.
Published: (2025-03-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

Hormone replacement therapy in women and risk of carpal tunnel syndrome: a systematic review and metaanalysis
by: Worapaka Manosroi, et al.
Published: (2023-06-01)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
by: Yuta Suzuki, et al.
Published: (2022-05-01)

Predictors and Predictive Score of In-Hospital Mortality in Diabetic Ketoacidosis: A Retrospective Cohort Study
by: Neera Munsakul, et al.
Published: (2024-11-01)

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
by: Oliver Schnell, et al.
Published: (2020-07-01)

A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
by: Jonali Ramani, et al.
Published: (2022-12-01)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
by: Panagiotis Theofilis, et al.
Published: (2023-02-01)

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
by: S. Ghosal, et al.
Published: (2018-05-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach
by: JÉSSICA B. DE JESUS, et al.
Published: (2022-10-01)

Role of SGLT2 inhibitors in improving cardiac functions (on Echocardiography) in patients having Diabetes Mellitus and ischemic heart disease
by: Muhammd Owais, et al.
Published: (2024-08-01)

Predictive model for prolonged length of hospital stay in patients with osteoporotic femoral neck fracture: A 5-year retrospective study
by: Worapaka Manosroi, et al.
Published: (2023-01-01)

A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes
by: Naveenkumar Nallathambi, et al.
Published: (2024-11-01)

Effect of SGLT2 inhibitor on patients with STEMI complicated with type 2 diabetes mellitus after PCI
by: Du Shengli, Jia Zengqin, Zhang Qihua
Published: (2023-04-01)

Impact of SGLT-2 inhibitors on modifiable cardiovascular risk factors in Romanian patients with type 2 diabetes mellitus
by: Adriana Gherbon, et al.
Published: (2024-04-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns
by: Farazul Hoda, et al.
Published: (2024-11-01)

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes
by: Mustafa Tanrıverdi, et al.
Published: (2023-10-01)

Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
by: James Shaffner, et al.
Published: (2021-11-01)

SGLT2i pharmacological treatment in type 2 diabetes mellitus control and its underlying obesity
by: Luiz Miguel Santiago, et al.
Published: (2024-04-01)

Diabetic ketoacidosis induced by SGLT2 inhibitors in acute ischemic stroke: a report of two cases
by: Jin-Heon Jeong
Published: (2024-12-01)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
by: Li N, et al.
Published: (2020-11-01)

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
by: Atsuo Tahara, et al.
Published: (2019-11-01)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
by: Ben A. Kappel, et al.
Published: (2021-06-01)

Psoriasiform lesions as a side effect of SGLT-2 therapy
by: Jakub Krzysztof Gałązka, et al.
Published: (2023-01-01)

Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report
by: Felice Nappi, et al.
Published: (2019-08-01)

Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
by: Carmela Morace, et al.
Published: (2024-05-01)

The extent of use of SGLT2 inhibitors in patients with type 2 diabetes in clinical practice: A study from India
by: Rutul Gokalani, et al.
Published: (2021-01-01)

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells
by: Aiko Seki, et al.
Published: (2025-01-01)

A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery
by: Deborah A. Osafehinti, MD, et al.
Published: (2021-01-01)

Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
by: Lana C. Pinto, et al.
Published: (2022-03-01)

Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
by: Siddhartha Dutta, et al.
Published: (2022-01-01)

Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
by: Samuel Seidu, et al.
Published: (2022-01-01)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
by: Chiara Maria Assunta Cefalo, et al.
Published: (2019-02-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)